Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia

Pregnancy Hypertension

Volumn 2, Issue 4, 2012, Pages 358-367

  Liu, Zhen ^a   Afink, Gijs B ^b   Dijke, Peter Ten ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Angiogenesis; Endothelial dysfunction; Pre eclampsia; sFlt1; Soluble endoglin; TGF ; VEGF

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ANGIOGENESIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERTENSION; NONHUMAN; PATHOGENESIS; PREDICTION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINURIA; REVIEW; RISK ASSESSMENT; RODENT; SCREENING; UPREGULATION;

EID: 84866614157     PISSN: 22107789     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.preghy.2012.06.003     Document Type: Review

References (124)

1. J.M. Roberts, G. Pearson, J. Cutler, and M. Lindheimer Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy Hypertens Pregnancy 41 2003 437 445
2. S. Baumwell, and S.A. Karumanchi Pre-eclampsia: clinical manifestations and molecular mechanisms Nephron Clin Pract 106 2007 c72-c81
3. B. Sibai, G. Dekker, and M. Kupferminc Pre-eclampsia Lancet 365 2005 785 799
4. J.J. Walker Pre-eclampsia Lancet 356 2000 1260 1265
5. G.C. Smith, J.P. Pell, and D. Walsh Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129, 290 births Lancet 357 2001 2002 2006
6. J.G. Ray, M.J. Vermeulen, M.J. Schull, and D.A. Redelmeier Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study Lancet 366 2005 1797 1803
7. R.J. Levine, C. Lam, and C. Qian Soluble endoglin and other circulating antiangiogenic factors in preeclampsia N Engl J Med 355 2006 992 1005
8. S.E. Maynard, J.Y. Min, and J. Merchan Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
9. S. Venkatesha, M. Toporsian, and C. Lam Soluble endoglin contributes to the pathogenesis of preeclampsia Nat Med 12 2006 642 649
10. C.W. Redman, and I.L. Sargent Immunology of pre-eclampsia Am J Reprod Immunol 63 2010 534 543
11. J. Woolard, H.S. Bevan, and S.J. Harper Molecular diversity of VEGF-A as a regulator of its biological activity Microcirculation 16 2009 572 592
12. K. Ballmer-Hofer, A.E. Andersson, and L.E. Berger Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output Blood 118 2011 816 826
13. S.S. Cebe, M. Pieren, and L. Cariolato A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2 Cell Mol Life Sci 63 2006 2067 2077
14. B. Favier, A. Alam, and P. Barron Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration Blood 108 2006 1243 1250
15. B. Herzog, C. Pellet-Many, and G. Britton VEGF binding to NRP1 is essential for VEGF stimulation of endothelial cell migration, complex formation between NRP1 and VEGFR2, and signaling via FAK Tyr40phosphorylation Mol Biol Cell 22 2011 2766 2776
16. H. Kawamura, X. Li, and K. Goishi Neuropilin-1 in regulation of VEGF-induced activation of p38MAPK and endothelial cell organization Blood 112 2008 3638 3649
17. C. Fischer, M. Mazzone, B. Jonckx, and P. Carmeliet FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 8 2008 942 956
18. A.K. Olsson, A. Dimberg, J. Kreuger, and L. Claesson-Welsh VEGF receptor signalling - in control of vascular function Nat Rev Mol Cell Biol 7 2006 359 371
19. E. Kukk, A. Lymboussak, and S. Taira VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development Development 122 1996 3829 3837
20. G.H. Fong, J. Rossant, and M. Gertsenstein Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium Nature 376 1995 66 70
21. F. Shalaby, J. Rossant, and J.P. Yamaguchi Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice Nature 376 1995 62 66
22. G. Fuh, B. Li, C. Crowley, and B. Cunningham Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor J Biol Chem 273 1998 11197 11204
23. H.W. Christinger, G. Fuh, and A.M. de Vos The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1 J Biol Chem 279 2004 10382 10388
24. C. Wiesmann, G. Fuh, and H.W. Christinger Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor Cell 91 1997 695 704
25. B. Li, G. Fuh, and G. Meng Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization J Biol Chem 275 2000 29823 29828
26. A. Sawano, S. Iwai, and Y. Sakurai Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans Blood 97 2001 785 791
27. L. Seetharam, N. Gotoh, and Y. Maru A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF Oncogene 10 1995 135 147
28. J. Waltenberger, L. Claesson-Welsh, and A. Siegbahn Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor J Biol Chem 269 1994 26988 26995
29. H. Gille, J. Kowalski, and L. Yu A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration EMBO J 19 2000 4064 4073
30. S. Hiratsuka, O. Minowa, and J. Kuno Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice Proc Natl Acad Sci U S A 95 1998 9349 9354
31. M. Autiero, J. Waltenberger, and D. Communi Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 Nat Med 9 7 2003 936 943
32. J.E. Park, H.H. Chen, and J. Winer Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR J Biol Chem 269 1994 25646 25654
33. A. Sawano, T. Takahashi, and S. Yamaguchi Flt-1 but not KDR/Flk-1 tyrosine kinase is a receptor for placenta growth factor, which is related to vascular endothelial growth factor Cell Growth Differ 7 1996 213 221
34. Q. Zhao, K. Egashira, and K. Hiasa Essential role of vascular endothelial growth factor and Flt-1 signals in neointimal formation after periadventitial injury Arterioscler Thromb Vasc Biol 24 2004 2284 2289
35. S. Hiratsuka, K. Nakamura, and S. Iwai MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis Cancer Cell 2 2002 289 300
36. J. Kami, K. Muranaka, and Y. Yanagi Inhibition of choroidal neovascularization by blocking vascular endothelial growth factor receptor tyrosine kinase Jpn J Ophthalmol 52 2008 91 98
37. M. Murakami, S. Iwai, and S. Hiratsuka Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages Blood 108 2006 1849 1856
38. J. Krueger, D. Liu, and K. Scholz Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo Development 138 2011 2111 2120
39. Y. He, S.K. Smith, K.A. Day, and D.E. Clark Alternative splicing of vascular endothelial growth factor (VEGF)-R1 (FLT-1) pre-mRNA is important for the regulation of VEGF activity Mol Endocrinol 13 1999 537 545
40. K. Kondo, S. Hiratsuka, and E. Subbalakshmi Genomic organization of the flt-1 gene encoding for vascular endothelial growth factor (VEGF) receptor-1 suggests an intimate evolutionary relationship between the 7-Ig and the 5-Ig tyrosine kinase receptors Gene 208 1998 297 305
41. M. Shibuya, S. Yamaguchi, and A. Yamane Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family Oncogene 5 1990 519 524
42. R.L. Kendall, and K.A. Thomas Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor Proc Natl Acad Sci U S A 90 1993 10705 10709
43. M. Shibuya Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1) Int J Biochem Cell Biol 33 2001 409 420
44. H. Itoh, K. Nasu, H. Matsumoto, and Y. Kawano Hypoxia regulates vascular endothelial growth factor and soluble fms-like tyrosine kinase-1 secretion by human oviductal epithelial cells and stromal fibroblasts Fertil Steril 85 Suppl. 1 2006 1097 1102
45. J.N. Boeckel, V. Guarani, and M. Koyanagi Jumonji domain-containing protein 6 (Jmjd6) is required for angiogenic sprouting and regulates splicing of VEGF-receptor 1 Proc Natl Acad Sci U S A 108 2011 3276 3281
46. O. Nevo, N. Soleymanlou, and Y. Wu Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 Am J Physiol Regul Integr Comp Physiol 291 2006 R1085-R1093
47. M. Heydarian, T. McCaffrey, and L. Florea Novel splice variants of sFlt1 are upregulated in preeclampsia Placenta 30 2009 250 255
48. S. Sela, A. Itin, and N. Natanson-Yaron A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia Circ Res 102 2008 1566 1574
49. J. Jebbink, R. Keijser, G. Veenboer, and J. van der Post Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth Hypertension 58 2011 70 76
50. N. Rahimi, T.E. Golde, and R.D. Meyer Identification of ligand-induced proteolytic cleavage and ectodomain shedding of VEGFR-1/FLT1 in leukemic cancer cells Cancer Res 69 2009 2607 2614
51. J. Holash, S. Davis, and N. Papadopoulos VEGF-Trap: a VEGF blocker with potent antitumor effects Proc Natl Acad Sci U S A 99 2002 11393 11398
52. G.S. Di Marco, S. Reuter, and U. Hillebrand The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD J Am Soc Nephrol 20 2009 2235 2245
53. C.K. Goldman, R.L. Kendall, and G. Cabrera Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate Proc Natl Acad Sci U S A 95 1998 8795 8800
54. C.M. Lai, W.Y. Shen, and M. Brankov Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys Mol Ther 12 2005 659 668
55. A.O. Afuwape, M. Feldmann, and E.M. Paleolog Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis Gene Ther 10 2003 1950 1960
56. M. El-Mousawi, L. Tchistiakova, and L. Yurchenko A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library J Biol Chem 278 2003 46681 46691
57. S. Helske, P. Vuorela, O. Carpen, and C. Hornig Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies Mol Hum Reprod 7 2001 205 210
58. K. Kumazaki, M. Nakayama, N. Suehara, and Y. Wada Expression of vascular endothelial growth factor, placental growth factor, and their receptors Flt-1 and KDR in human placenta under pathologic conditions Hum Pathol 33 11 2002 1069 1077
59. V. Taché, D.Y. LaCoursiere, A. Saleemuddin, and M.M. Parast Placental expression of vascular endothelial growth factor receptor-1/soluble vascular endothelial growth factor receptor-1 correlates with severity of clinical preeclampsia and villous hypermaturity Hum Pathol 42 9 2011 1283 12888
60. D.E. Clark, S.K. Smith, and Y. He A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation Biol Reprod 59 1998 1540 1548
61. F. Lebrin, M.J. Goumans, and L. Jonker Endoglin promotes endothelial cell proliferation and TGF-β/ALK1 signal transduction EMBO J 23 2004 4018 4028
62. C.H. Heldin, K. Miyazono, and P. ten Dijke TGF-β signalling from cell membrane to nucleus through SMAD proteins Nature 390 1997 465 471
63. A. Gougos, and M. Letarte Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line J Immunol 141 1988 1925 1933
64. M. Guerrero-Esteo, T. Sanchez-Elsner, A. Letamendia, and C. Bernabeu Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-β receptors I and II J Biol Chem 277 2002 29197 29209
65. P. Lastres, A. Letamendía, H. Zhang, C. Rius, N. Almendro, and U. Raab Endoglin modulates cellular responses to TGF-β1 J Cell Biol 133 1996 1109 1121
66. M. Scharpfenecker, M. van Dinther, and Z. Liu BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis J Cell Sci 120 2007 964 972
67. P. ten Dijke, M.J. Goumans, and E. Pardali Endoglin in angiogenesis and vascular diseases Angiogenesis 11 2008 79 89
68. E. Perez-Gomez, N. Eleno, and J.M. Lopez-Novoa Characterization of murine S-endoglin isoform and its effects on tumor development Oncogene 4 2005 4450 4461
69. S. Velasco, P. Alvarez-Munoz, and M. Pericacho L- and S-endoglin differentially modulate TGF-β1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts J Cell Sci 121 2008 913 919
70. A. Gougos, S. St-Jacques, and A. Greaves Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts Int Immunol 4 1992 83 92
71. S. St-Jacques, U. Cymerman, and N. Pece Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells Endocrinology 134 1994 2645 2657
72. M.M. Robledo, A. Hidalgo, and P. Lastres Characterization of TGF-β1-binding proteins in human bone marrow stromal cells Br J Haematol 93 1996 507 551
73. P. Lastres, T. Bellon, and C. Cabanas Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen Eur J Immunol 22 1992 393 397
74. S.E. Duff, C. Li, J.M. Garland, and S. Kumar CD105 is important for angiogenesis: evidence and potential applications FASEB J 17 2003 984 992
75. T. Sanchez-Elsner, L.M. Botella, and B. Velasco Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways J Biol Chem 277 2002 43799 43808
76. Y. Yinon, O. Nevo, and J. Xu Severe intrauterine growth restriction pregnancies have increased placental endoglin levels: hypoxic regulation via transforming growth factor-β3 Am J Pathol 172 2008 77 85
77. M. Jerkic, J.V. Rivas-Elena, and M. Prieto Endoglin regulates nitric oxide-dependent vasodilatation FASEB J 18 2004 609 611
78. M. Jerkic, A. Rodriguez-Barbero, and M. Prieto Reduced angiogenic responses in adult endoglin heterozygous mice Cardiovasc Res 69 2006 845 854
79. C. Li, I.N. Hampson, L. Hampson, and P. Kumar CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human vascular endothelial cells FASEB J 14 2000 55 64
80. H.M. Arthur, J. Ure, and A.J. Smith Endoglin, an ancillary TGF-β receptor, is required for extraembryonic angiogenesis and plays a key role in heart development Dev Biol 217 2000 42 53
81. A. Bourdeau, M.E. Faughnan, and M. Letarte Endoglin-deficient mice, a unique model to study hereditary hemorrhagic telangiectasia Trends Cardiovasc Med 10 2000 279 285
82. D.Y. Li, L.K. Sorensen, and B.S. Brooke Defective angiogenesis in mice lacking endoglin Science 284 1999 1534 1537
83. K.A. McAllister, K.M. Grogg, and D.W. Johnson Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1 Nat Genet 8 1994 345 351
84. E. Fonsatt, M. Altomonte, and M.R. Nicotra Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels Oncogene 22 2003 6557 6563
85. N. Takahashi, A. Haba, F. Matsuno, and B.K. Seon Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide Cancer Res 61 2001 7846 7854
86. L.J. Hawinkels, P. Kuiper, and E. Wiercinska Matrix metalloproteinase-14 (MT1-MMP)-mediated endoglin shedding inhibits tumor angiogenesis Cancer Res 70 2010 4141 4150
87. T.J. Kaitu'u-Lino, K.R. Palmer, and C.L. Whitehead MMP-14 Is expressed in preeclamptic placentas and mediates release of soluble endoglin Am J Pathol 180 2012 888 894
88. R. Castonguay, E.D. Werner, and R.G. Matthews Soluble endoglin specifically binds BMP9/BMP10 via its orphan domain, inhibits blood vessel formation and suppresses tumor growth J Biol Chem 286 2011 30034 30046
89. T.E. Walshe, M. Saint-Geniez, and A.S. Maharaj TGF-β is required for vascular barrier function, endothelial survival and homeostasis of the adult microvasculature PLoS One 4 2009 e5149
90. M. Potente, H. Gerhardt, and P. Carmeliet Basic and therapeutic aspects of angiogenesis Cell 146 6 2011 873 887
91. P. ten Dijke, and H.M. Arthur Extracellular control of TGF-β signalling in vascular development and disease Nat Rev Mol Cell Biol 8 2007 857 869
92. K. Koga, Y. Osuga, and O. Yoshino Elevated serum soluble vascular endothelial growth factor receptor 1 (sVEGFR-1) levels in women with preeclampsia J Clin Endocrinol Metab 88 2003 2348 2351
93. V. Tsatsaris, F. Goffin, and C. Munaut Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences J Clin Endocrinol Metab 88 2003 5555 5563
94. O. Lapaire, A. Shennan, and H. Stepan The preeclampsia biomarkers soluble fms-like tyrosine kinase-1 and placental growth factor: current knowledge, clinical implications and future application Eur J Obstet Gynecol Reprod Biol 151 2010 122 129
95. R.N. Taylor, J. Grimwood, and R.S. Taylor Longitudinal serum concentrations of placental growth factor: evidence for abnormal placental angiogenesis in pathologic pregnancies Am J Obstet Gynecol 188 2003 177 182
96. H. Strevens, D. Wide-Swensson, and A. Hansen Glomerular endotheliosis in normal pregnancy and pre-eclampsia BJOG 110 2003 831 836
97. R. Tal, A. Shaish, and I. Barshack Effects of hypoxia-inducible factor-1β overexpression in pregnant mice. possible implications for preeclampsia and intrauterine growth restriction Am J Pathol 177 2010 2950 2962
98. J. Rossant, and J.C. Cross Placental development: lessons from mouse mutants Nat Rev Genet 2 2001 538 548
99. H. Sugimoto, Y. Hamano, and D. Charytan Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria J Biol Chem 278 2003 12605 12608
100. J.S. Gilbert, S.A. Gilbert, M. Arany, and J.G. Granger Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression Hypertension 53 2009 399 403
101. A. Bergmann, S. Ahmad, and M. Cudmore Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model J Cell Mol Med 14 2010 1857 1867
102. N. Sunderland, A. Hennessy, and A. Makris Animal models of pre-eclampsia Am J Reprod Immunol 65 2011 533 541
103. G. Losonczy, G. Brown, and R.C. Venuto Increased peripheral resistance during reduced uterine perfusion pressure hypertension in pregnant rabbits Am J Med Sci 303 1992 233 240
104. M.M. Abitbol A simplified technique to produce toxemia in the pregnant dog Am J Obstet Gynecol 139 1981 526 534
105. L.L. Woods, and V.L. Brooks Role of the renin-angiotensin system in hypertension during reduced uteroplacental perfusion pressure Am J Physiol 257 1989 R204-R209
106. C.A. Combs, M.A. Katz, J.L. Kitzmiller, and R.J. Brescia Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys Am J Obstet Gynecol 169 1993 215 223
107. D. Cavanagh, P.S. Rao, C.C. Tsai, and T.C. O'Connor Experimental toxemia in the pregnant primate Am J Obstet Gynecol 128 1977 75 85
108. J.S. Gilbert, S.A. Babcock, and J.P. Granger Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression Hypertension 50 2007 1142 1147
109. C.D. Thatcher, and J.C. Keith Jr. Pregnancy-induced hypertension: development of a model in the pregnant sheep Am J Obstet Gynecol 155 1986 201 207
110. C.C. Zhou, Y. Zhang, and R.A. Irani Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice Nat Med 14 2008 855 862
111. C.C. Zhou, R.A. Irani, and Y. Zhang Angiotensin receptor agonistic autoantibody-mediated tumor necrosis factor-alpha induction contributes to increased soluble endoglin production in preeclampsia Circulation 121 2010 436 444
112. J. Schiettecatte, H. Russcher, and E. Anckaert Multicenter evaluation of the first automated Elecsys sFlt-1 and PlGF assays in normal pregnancies and preeclampsia Clin Biochem 43 2010 768 770
113. S. Verlohren, A. Galindo, and D. Schlembach An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia Am J Obstet Gynecol 202 2010 161
114. S.E. Maynard, T.A. Moore Simas, and L. Bur Soluble endoglin for the prediction of preeclampsia in a high risk cohort Hypertens Pregnancy 29 2010 330 341
115. J.H. Lim, S.Y. Kim, and S.Y. Park Effective prediction of preeclampsia by a combined ratio of angiogenesis-related factors Am J Obstet Gynecol 111 2008 1403 1409
116. S. Salahuddin, Y. Lee, and M. Vadnais Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy Am J Obstet Gynecol 197 2007 28-26
117. H. Stepan, T. Kramer, and R. Faber Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction J Clin Endocrinol Metab 92 2007 2831 2834
118. A. Jeyabalan, S. McGonigal, and C. Gilmour Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia Placenta 29 2008 555 563
119. A.M. Blazquez-Medela, L. Garcia-Ortiz, and M.A. Gomez-Marcos Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients BMC Med 8 2010 86
120. A. Ohkuchi, C. Hirashima, and S. Matsubara Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria Hypertens Pregnancy 28 2009 95 108
121. M.J. Cudmore, S. Ahmad, and B. Al-Ani Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1 Circulation 115 2007 1789 1797
122. M.J. Cudmore, S. Ahmad, and S. Sissaoui Loss of Akt activity increases circulating soluble endoglin release in preeclampsia: identification of inter-dependency between Akt-1 and heme oxygenase-1 Eur Heart J 2011
123. A. Ahmed New insights into the etiology of preeclampsia: identification of key elusive factors for the vascular complications Thromb Res 127 2011 S72 S75
124. N. Grosser, A. Hemmerle, and G. Berndt The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells Free Radic Biol Med 37 2004 2064 2071